262 related articles for article (PubMed ID: 35053188)
1. Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?
Tripathi A; Fanning S; Dettmer U
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053188
[TBL] [Abstract][Full Text] [Related]
2. MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy.
Kula J; Kuter KZ
Neuropharmacology; 2024 May; 249():109865. PubMed ID: 38342377
[TBL] [Abstract][Full Text] [Related]
3. Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor.
Terry-Kantor E; Tripathi A; Imberdis T; LaVoie ZM; Ho GPH; Selkoe D; Fanning S; Ramalingam N; Dettmer U
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707907
[TBL] [Abstract][Full Text] [Related]
4. Vesicle trafficking and lipid metabolism in synucleinopathy.
Fanning S; Selkoe D; Dettmer U
Acta Neuropathol; 2021 Apr; 141(4):491-510. PubMed ID: 32607605
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
6. More than meets the eye in Parkinson's disease and other synucleinopathies: from proteinopathy to lipidopathy.
Flores-Leon M; Outeiro TF
Acta Neuropathol; 2023 Sep; 146(3):369-385. PubMed ID: 37421475
[TBL] [Abstract][Full Text] [Related]
7. Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity.
Kim TE; Newman AJ; Imberdis T; Brontesi L; Tripathi A; Ramalingam N; Fanning S; Selkoe D; Dettmer U
Hum Mol Genet; 2021 Nov; 30(23):2332-2346. PubMed ID: 34254125
[TBL] [Abstract][Full Text] [Related]
8.
Granek Z; Barczuk J; Siwecka N; Rozpędek-Kamińska W; Kucharska E; Majsterek I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768367
[TBL] [Abstract][Full Text] [Related]
9. Crowded organelles, lipid accumulation, and abnormal membrane tubulation in cellular models of enhanced α-synuclein membrane interaction.
Ericsson M; von Saucken V; Newman AJ; Doehr L; Hoesch C; Kim TE; Dettmer U
Brain Res; 2021 May; 1758():147349. PubMed ID: 33571519
[TBL] [Abstract][Full Text] [Related]
10. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
11. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
Molecules; 2020 May; 25(10):. PubMed ID: 32456274
[TBL] [Abstract][Full Text] [Related]
12. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment.
Fanning S; Haque A; Imberdis T; Baru V; Barrasa MI; Nuber S; Termine D; Ramalingam N; Ho GPH; Noble T; Sandoe J; Lou Y; Landgraf D; Freyzon Y; Newby G; Soldner F; Terry-Kantor E; Kim TE; Hofbauer HF; Becuwe M; Jaenisch R; Pincus D; Clish CB; Walther TC; Farese RV; Srinivasan S; Welte MA; Kohlwein SD; Dettmer U; Lindquist S; Selkoe D
Mol Cell; 2019 Mar; 73(5):1001-1014.e8. PubMed ID: 30527540
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid Homeostasis.
Tripathi A; Alnakhala H; Terry-Kantor E; Newman A; Liu L; Imberdis T; Fanning S; Nuber S; Ramalingam N; Selkoe D; Dettmer U
J Neurosci; 2022 Mar; 42(10):2116-2130. PubMed ID: 35086904
[TBL] [Abstract][Full Text] [Related]
14. Cell models of lipid-rich α-synuclein aggregation validate known modifiers of α-synuclein biology and identify stearoyl-CoA desaturase.
Imberdis T; Negri J; Ramalingam N; Terry-Kantor E; Ho GPH; Fanning S; Stirtz G; Kim TE; Levy OA; Young-Pearse TL; Selkoe D; Dettmer U
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20760-20769. PubMed ID: 31548371
[TBL] [Abstract][Full Text] [Related]
15. Development of targeted therapies for Parkinson's disease and related synucleinopathies.
Sybertz E; Krainc D
J Lipid Res; 2014 Oct; 55(10):1996-2003. PubMed ID: 24668939
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
18. Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.
Sekigawa A; Takamatsu Y; Sekiyama K; Hashimoto M
Biomolecules; 2015 May; 5(2):1000-11. PubMed ID: 25996784
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease: proteinopathy or lipidopathy?
Fanning S; Selkoe D; Dettmer U
NPJ Parkinsons Dis; 2020; 6():3. PubMed ID: 31909184
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Kawahata I; Finkelstein DI; Fukunaga K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
